ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 662,30
-0,58%
Dow Jones
39 112,16
-0,76%
DAX
18 177,62
-0,90%
Brent Oil
84,185
-1,27%
Bitcoin
61 696,69
2,38%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. L'Europe
  5. EU
  6. Vivoryon Therapeut (VVY)

  7. Vivoryon Therapeut (VVY) Actualités

VVY

Vivoryon Therapeut (VVY)

Vivoryon Therapeut
De:
Trier par:
 Showing the most relevant articles for your search:EU:VVY
DateHeureSourceTitreSymboleSociété
21/06/202415h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General MeetingEU:VVYVivoryon Therapeut
23/05/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney DiseaseEU:VVYVivoryon Therapeut
15/05/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024EU:VVYVivoryon Therapeut
08/05/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024EU:VVYVivoryon Therapeut
24/04/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic UpdatesEU:VVYVivoryon Therapeut
16/04/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024EU:VVYVivoryon Therapeut
15/03/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Changes to Board CompositionEU:VVYVivoryon Therapeut
04/03/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
08/01/202407h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024EU:VVYVivoryon Therapeut
06/12/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
28/11/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023EU:VVYVivoryon Therapeut
07/11/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
26/10/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose DecisionEU:VVYVivoryon Therapeut
23/10/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
17/10/202315h32GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
05/10/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
15/09/202313h57GlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the BoardEU:VVYVivoryon Therapeut
07/09/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
31/08/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023EU:VVYVivoryon Therapeut
04/08/202323h35GlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023EU:VVYVivoryon Therapeut
04/08/202323h30GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive OfficerEU:VVYVivoryon Therapeut
16/07/202309h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
21/06/202318h02GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General MeetingEU:VVYVivoryon Therapeut
15/06/202317h49GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces CEO Transition PlanEU:VVYVivoryon Therapeut
01/06/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Participate in Upcoming ConferencesEU:VVYVivoryon Therapeut
26/05/202307h39GlobeNewswire Inc.Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 MillionEU:VVYVivoryon Therapeut
25/05/202317h50GlobeNewswire Inc.Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild OfferingEU:VVYVivoryon Therapeut
16/05/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
09/05/202307h02GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023EU:VVYVivoryon Therapeut
09/05/202307h00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023EU:VVYVivoryon Therapeut
 Showing the most relevant articles for your search:EU:VVY

Dernières Valeurs Consultées

EU
PABU5
Euronext PAB North Ameri...
USOTC
BORUF
Borussia Dortmund (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés